Trials / Conditions / Type I Hypersensitivity

Type I Hypersensitivity

17 registered clinical trials studyying Type I Hypersensitivity.

Status	Trial	Sponsor	Phase
Completed	Efficacy and Safety/Tolerability of Ragweed MATA MPL NCT00423787	Allergy Therapeutics	Phase 3
Completed	Efficacy and Safety/Tolerability of Grass MATA MPL NCT00414141	Allergy Therapeutics	Phase 3
Terminated	Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Sea NCT00387478	Allergy Therapeutics	Phase 2
Completed	Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal A NCT00325338	Allergy Therapeutics	Phase 2
Completed	Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen NCT00241410	Allergy Therapeutics	Phase 1
Completed	Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Usi NCT00258635	Allergy Therapeutics	Phase 2
Completed	Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine NCT00133146	Allergy Therapeutics	Phase 2
Completed	Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sens NCT00133159	Allergy Therapeutics	Phase 2
Completed	Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensi NCT00118612	Allergy Therapeutics	Phase 2
Completed	Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine NCT00118625	Allergy Therapeutics	Phase 2
Completed	Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen NCT00113750	Allergy Therapeutics	Phase 2
Completed	Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin NCT00116285	Allergy Therapeutics	Phase 1
Withdrawn	Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl L NCT00109759	Allergy Therapeutics	Phase 1
Completed	Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Aller NCT00110786	Allergy Therapeutics	Phase 2
Completed	Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testi NCT00107705	Allergy Therapeutics	Phase 1
Completed	Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen NCT00104377	Allergy Therapeutics	Phase 2
Completed	Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing NCT00104390	Allergy Therapeutics	Phase 1